



**The Australian Group on Antimicrobial Resistance**

<http://antimicrobial-resistance.com>

---

# **AGAR Financial Report December 2011 Quarterly Financial Report**

**Prepared by: Geoffrey Coombs, AGAR Treasurer**

**Presented: AGAR Executive. 10 May 2012**

# ASA

Australian Society for Antimicrobials

ABN: 31 081 739 370



**PO Box 8266,  
Angelo St  
South Perth  
Western Australia 6151**

**☎ (08) 9224 2446**

**FAX: (08) 9450 8553**

**📧 [info@asainc.net.au](mailto:info@asainc.net.au)**

## **AGAR Financial Report December 2011 Quarterly Financial Report**

	<b>GST incl</b>	<b>GST</b>
<b>Income to 31<sup>st</sup> December 2011</b>		
MSD		
2011 Ertapenem Study		
1 <sup>st</sup> Payment	15,345.00	1,395.00
AstraZeneca		
2011 Cefabiprole Study		
1 <sup>st</sup> Payment	14,667.40	1,333.40
Bank		
Cash Reserve Account (AGAR)	79.86	0.00
<b>Total Income</b>	<b>30,092.26</b>	<b>2,728.40</b>
<b>Total Income (excluding GST)</b>	<b>27,363.86</b>	
<b>Expenditure to 31<sup>st</sup> December 2011</b>		
AGAR November 2011 Committee Meeting		
Airfares	3,902.47	354.77
Venue	9,472.36	861.13
Administration	500.00	0.00
AGAR SAP 2009		
Susceptibility Report	118.85	10.80
AGAR SAP 2010		
Referring Laboratories (5)	2,700.00	200.00

AGAR GNR 2010		
Referring Laboratories (4)	2,183.50	198.50
AGAR AESOP 2011		
Referring Laboratories (1)	649.00	59.00
MSD Ertapenem 2010 Study		
Referring Laboratories (12)	13,067.00	1,097.00
AGAR SAP 2011		
Molecular Typing	14,964.40	860.40
AGAR Website	600.00	0.00
<b>Total Expenses</b>	<b>48,157.58</b>	<b>3,641.60</b>
<b>Total Expenses (excluding GST)</b>	<b>44,515.98</b>	
<b>Net Expense</b>	<b>17,152.12</b>	



The Australian Group on Antimicrobial Resistance

# ASA

Australian Society for Antimicrobials  
ABN: 31 081 739 370



**PO Box 8266,  
Angelo St  
South Perth  
Western Australia 6151**

**☎ (08) 9224 2446**

**FAX: (08) 9450 8553**

**✉ [info@asainc.net.au](mailto:info@asainc.net.au)**

## **AGAR Financial Report December 2011 Quarterly Financial Report**

### **FUNDS**

#### **Accumulated Funds 31<sup>st</sup> December 2011**

**Balance as at 30<sup>th</sup> September 2011 (462.21)**

**Net Expenses (17,152.12)**

**Balance as at 31<sup>st</sup> December 2011 (17,614.33)**

**Current Funds: 994.06 AstraZeneca Web Page  
9,490.00 Daptomycin 2008 and 2009  
10,075.00 Ertapenem 2010  
865.00 Ertapenem 2011  
(39,038.39) AGAR Funds**

**Figures exclude GST**



**The Australian Group on Antimicrobial Resistance**